Remitoro
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, T-cell, Peripheral
Conditions
Lymphoma, T-cell, Peripheral, Lymphoma, T-cell, Cutaneous
Trial Timeline
May 24, 2021 → Mar 17, 2023
NCT ID
NCT05137847About Remitoro
Remitoro is a pre-clinical stage product being developed by Eisai for Lymphoma, T-cell, Peripheral. The current trial status is completed. This product is registered under clinical trial identifier NCT05137847. Target conditions include Lymphoma, T-cell, Peripheral, Lymphoma, T-cell, Cutaneous.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05137847 | Pre-clinical | Completed |
Competing Products
20 competing products in Lymphoma, T-cell, Peripheral